Kids From Poorer Families Less Likely to Survive Cancer

2024-07-26
FRIDAY, July 26, 2024 -- Children from poor families are less likely to survive cancer, particularly if they are not white, a new study reports.
A childhood cancer patient’s risk of dying within five years of their diagnosis increases 4% for every one-point increase in their neighborhood’s Area Deprivation Index (ADI), researchers found.
The ADI uses 17 factors to measure a patient’s background, with higher scores indicating greater economic uncertainty, researchers said.
Results also showed that non-white children had an increased risk of death from cancer.
“Despite significant progress in the treatment of pediatric cancer, socioeconomic factors continue to cause outcome disparities,” said researcher Dr. Dai Chung, a professor of surgery at UT Southwestern Medical Center in Dallas.
For the study, researchers analyzed Texas Cancer Registry records of nearly 3,900 children diagnosed with tumors between 1995 and 2019. The average age at diagnosis was 4 and a half years old.
Poor and minority kids also had an increased risk of their cancer spreading to other parts of their bodies, as well as children living in rural areas or areas near the Texas-Mexico border.
That could be because those groups are more likely to have a delay in their cancer treatment, researchers said.
For example, among all sarcoma patients the median time between diagnosis and start of treatment was three days.
But treatment began more than 51 days later for Black children compared to white kids, and 34 days later for rural kids compared to city children, the study found.
The new study was published recently in the Journal of the American College of Surgeons.
“Our hope is that our study findings can motivate improvements in racial and socioeconomic diversity in pediatric cancer clinical trials, increase funding for disparities in outcomes research, and implement ground-level changes that will make health care more accessible for all patients,” Chung said.
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。